555B Stock Epinephrine Auto-Injector Supply for Anaphylaxis

555B

STOCK EPINEPHRINE AUTO-INJECTOR SUPPLY FOR ANAPHYLAXIS
 

I. DEFINITION

Anaphylaxis is a medical emergency that requires immediate medical attention and can be fatal if not treated. This allergic emergency can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or unknown causes. Some people are at an increased risk for anaphylaxis because of known allergens. Some people with unknown allergies may experience their first reaction while at school. Symptoms generally appear quickly and progress rapidly. Early recognition of symptoms and immediate treatment can save a life! Symptoms may include:

  • LUNGS: shortness of breath, wheezing, repetitive cough
  • HEART: pale, blue, faint, weak pulse, dizzy
  • THROAT: tight, hoarse, difficulty breathing and/or swallowing
  • MOUTH: swelling of the tongue and/or lips
  • SKIN: hives, widespread redness
  • GUT: vomiting, diarrhea, discomfort
  • OTHER: feeling of “impending doom,” anxiety, confusion

II. INFORMATION/ GUIDELINES
The district will implement a protocol to respond to life-threatening allergic reactions (anaphylaxis). The school will maintain the medication necessary to apply the protocol in each school building.  This protocol would apply to any individual present in the facility while school is in session. This protocol does NOT extend to activities off school grounds (including transportation to and from school, field trips, etc.) or outside the academic day (sporting events, extra-curricular activities, etc.).

The district school nurse or other trained and authorized personnel may administer an epinephrine auto-injector from the school’s supply to a student or other individual if reasonably and in good faith believe the student or individual is having an anaphylactic reaction. Individuals authorized to administer the epinephrine will complete the appropriate medication training and be signed off by the school nurse.

The district will obtain and keep on file a prescription and standing order for the stock epinephrine from a licensed healthcare professional. A new prescription will be obtained annually.

The district will store the epinephrine auto-injectors in a secured, room temperature area that is accessible in an emergency within each school building. The medication will be checked monthly for stability and effectiveness.

III. EQUIPMENT

  • Epinephrine 0.15mg IM (intramuscular) for 55 pounds or less. 
  • Epinephrine 0.30mg IM (intramuscular) for 55 pounds or greater.

 

IV. PROCEDURE
Epinephrine injection is the treatment for anaphylaxis. Everyone with a known history of anaphylaxis or any severe allergies should have a specific emergency action plan on file and their own auto-injector of epinephrine at school.  For these individuals with known allergies, follow their personalized emergency action plan.
For individuals without a known allergy:           

  • Rapidly assess airway, breathing, and circulation and begin CPR as necessary. CALL 911 IMMEDIATELY.
  • Inject Epinephrine IMMEDIATELY. Do not leave the individual alone.
  • Lay the person flat, elevate legs, and keep warm.
  • If symptoms do not improve, or if symptoms return, an additional dose of epinephrine can be given 5 minutes or more after the last dose.
  • Appoint someone to notify emergency contacts.
  • Transport the individual to the emergency room, even if symptoms resolve.
  • Send used Epinephrine auto-injector with emergency personnel.

 

V. REPORTING
If a stock epinephrine auto-injector is utilized, the administration will be documented and reported to the state using the Iowa Department of Education’s “Report of Stock Epinephrine Administration” form.

As provided by law, the district, board, authorized personnel or school nurse, and the prescriber shall not be liable for any injury arising from the provision, administration, failure to administer, or assistance in the administration of an epinephrine auto-injector provided they acted reasonably and in good faith. 

 

REVIEWED: 06/17/2024 – APPROVED: 07/15/2024